Shanghai Fosun Pharmaceutical (SHA:600196) posted third-quarter net profit attributable to shareholders of 785.8 million yuan, up 55% from the previous year.
The pharmaceutical company's Q3 earnings per share climbed 53% year over year to 0.29 yuan, according to a Tuesday filing with the Shanghai bourse.
Revenue rose 12% on year to 10.5 billion yuan.
Shares of Shanghai Fosun Pharmaceutical rose 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments